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reamble
ranting clinical staff privileges to physicians is a primary
echanism institutions use to uphold quality care. The Joint
ommission on Accreditation of Healthcare Organizations
equires that medical staff privileges be based on profes-
ional criteria specified in medical staff bylaws. Physicians
hemselves are charged with defining the criteria that
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heir peers accordingly. The process of evaluating physi-
ians’ knowledge and competence has become more com-
lex as various subspecialties have evolved over time.
The American College of Cardiology Foundation
ACCF)/American Heart Association (AHA)/American
ollege of Physicians (ACP) Task Force on Clinical Com-
etence and Training was formed in 1998 to develop
ecommendations for attaining and maintaining the cogni-
ive and technical skills necessary for the competent perfor-
ance of a specific cardiovascular service, procedure, or
echnology. These documents are evidence based, and
here evidence is not available, expert opinion is used to
ormulate recommendations. Indications for and contrain-
ications to specific services or procedures are not included
n the scope of these documents. Recommendations are
ntended to assist those who must judge the competence of
ardiovascular healthcare providers entering practice for the
rst time and/or those in practice undergoing periodic
eview of their expertise. The assessment of competence is
omplex and multidimensional; therefore, isolated recom-
endations contained herein may not necessarily be suffi-
ient or appropriate for judging overall competence. The
urrent document addresses competence in the management
f patients with advanced heart failure (HF) and those
ndergoing cardiac transplantation and is authored by
epresentatives of the ACCF, ACP, AHA, Heart Failure
ociety of America (HFSA), and the International Society
or Heart and Lung Transplantation (ISHLT). Compe-
ence in the management of advanced HF in special
opulations such as children and patients with primary
ulmonary hypertension and congenital heart disease is
ddressed in several sections; however, comprehensive rec-
mmendations for competence in these areas are beyond the
cope of this document. Advanced HF and heart transplan-
ation are now formally linked, though there are many
ighly competent experts in the care of patients with HF
ho do not manage patients during or after heart transplan-
ation. The first board examination for certification in
dvanced HF and heart transplantation is scheduled for
ovember 8, 2010. The ACCF/AHA/ACP Task Force
akes every effort to avoid actual or potential conflicts of
nterest that may arise as a result of outside relationships or
ersonal interests of members of the writing committee.
pecifically, all members of the writing committee were
sked to disclose all such relationships that might be
erceived as real or potential conflicts of interest relevant to
he documented topic. These are reviewed by the writing
ommittee and updated as changes occur. The relationships
ith industry information for authors and peer reviewers are
ublished in Appendix 1 and 2, respectively.
Jonathan L. Halperin, MD, FACC, FAHA
Chair, ACCF/AHA/ACP Task Force
on Clinical Competence and Training t. Introduction
.1. Writing Committee Organization
he writing committee consisted of acknowledged experts
n the field of HF and cardiac transplantation, including 1
iaison from the ACCF/AHA/ACP Task Force on Clinical
ompetence and Training—the oversight group for this
ocument—3 ACCF representatives, 3 AHA representa-
ives, 3 HFSA representatives, 2 ISHLT representatives,
nd 1 ACP representative. Representation by an outside
rganization does not necessarily imply endorsement.
.2. Document Development Process
.2.1. Relationships With Industry and Other Entities
t its first meeting, each member of the writing committee
eported all relationships with industry and other entities
elevant to this document topic. This information was
pdated, if applicable, at the beginning of all subsequent
eetings and full-committee conference calls. As noted in
he Preamble, relevant relationships with industry and other
ntities of writing committee members are published in
ppendix 1.
.2.2. Consensus Development
uring the first meeting, the committee discussed the topics
o be covered in the document and assigned lead authors for
ach section. Authors conducted literature searches and
rafted their sections of the document outline. Over a series
f meetings and conference calls, the writing committee
eviewed each section, discussed document content, and
ltimately arrived at consensus on a document that was sent
or external peer review. Following peer review, the writing
ommittee chair engaged authors to address reviewer com-
ents and finalize the document for document approval by
articipating organizations.
.2.3. External Peer Review
his document was reviewed by 12 official representatives
rom the ACCF, ACP, AHA, HFSA, and ISHLT; as well
s 5 additional content reviewers, resulting in 208 peer
eview comments. See the list of peer reviewers, affiliations
or the review process, and corresponding relationships with
ndustry and other entities in Appendix 2. These comments
ere entered into a table and reviewed in detail by the
riting committee chair. The chair engaged writing com-
ittee members to respond to peer review comments. The
ocument was revised to incorporate reviewer comments
here deemed appropriate by the writing committee
In addition, a member of the ACCF Task Force on
linical Expert Consensus Documents (TF CECD) served
s lead reviewer for this document. This person conducted
n independent review of the document at the time of peer
eview. Once the writing committee documented its re-
ponse to reviewer comments and updated the manuscript,
he lead reviewer assessed whether all peer review issues
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July 27, 2010:424–53 Competence for Heart Failure and Transplantationere handled adequately or whether there were gaps that
equired additional review. The lead reviewer reported to
he chair of the ACCF TF CECD that all comments were
andled appropriately and recommended that the document
o forward for final review and sign-off.
.2.4. Final Writing Committee and Task Force
ign-Off on Document
he writing committee formally signed off on the final
ocument, as well as the relationships with industry that
ould be published with the document. The ACCF TF
ECD also reviewed and formally approved the document
o be sent for organizational approval.
.2.5. Document Approval
he final version of the document, along with the peer
eview comments and responses to comments were circu-
ated to the participating organizations for review and
pproval. The document was approved for publication by
he ACCF and AHA in June 2010 and the ACP in April
010. The document was then sent to the governing boards
f the HFSA and ISHLT for endorsement consideration,
long with the peer review comments and responses for
heir respective official peer reviewers. HFSA and ISHLT
ormally endorsed this document in May 2010. This docu-
ent will be considered current until the ACCF TF CECD
evises it or withdraws it from publication.
.3. Document Overview
his statement is the first ACCF/AHA/ACP/HFSA/
SHLT document on clinical competence for management
f patients with advanced HF and cardiac transplantation.
hese patients, defined essentially as having Stage D HF,
re usually hospitalized with refractory HF requiring spe-
ialized interventions. For example, they may be candidates
or intra-aortic balloon counterpulsation or other external
umping devices, ultrafiltration, dialysis, mechanical sup-
ort devices, experimental surgery, experimental drugs,
ransplantation, and end-of-life measures such as hospice
are. This statement is not meant to limit physicians who
are for patients with Stage A, B, and C HF. Moreover,
atients with earlier stages of cardiomyopathy may require a
F specialist to be involved in their care when there is a
eed for specialized genetic counseling for complex inher-
ted disease or other requirements because of complex,
nique features. Patients with Stage D HF often receive
omplicated drug regimens and often have implanted
ardioverter-defibrillators (ICDs) or biventricular pacemak-
rs. The current statement describes the level of experience,
nowledge, and technical skills necessary for competent
erformance in caring for these complex patients. When no
iterature or data are available upon which to base the
valuation of competence, the specifications are based on
onsensus of expert opinion. The specifications are applica-
le to various practice settings and training backgrounds and
ccommodate a number of ways physicians can demonstrate pompetence. Expertise in specific, uncommonly performed
rocedures or unusual diagnoses in patients with advanced
F or following heart transplantation may require addi-
ional training or experience. Therefore, it is expected that
ven highly competent practitioners will occasionally benefit
rom consultation with colleagues who have specialized
kills, such as in sleep medicine.
This document describes competence of HF specialists
ho have completed formal training in clinical cardiology
nd in some cases have completed additional training in
dvanced HF and heart transplantation. The committee
ecognizes that there are very capable cardiologists who do
ot have formal training in advanced HF and heart trans-
lantation but who care for patients with Stage D HF
ailure. The American Board of Internal Medicine (ABIM)
lans to accommodate such physicians toward certification
hrough various alternative pathways based on their overall
raining and experience; however, it is our expectation that
ventually certification will depend on formal training and
esting. Training guidelines are distinguished from compe-
ence statements. Training guidelines are covered in the
ore Cardiology Training Statement (COCATS) for car-
iology training and HF/transplantation (1). This docu-
ent also addresses additional competencies required for
he care of special populations of patients with advanced
F, such as children or those with primary pulmonary
ypertension or congenital heart diseases, but it should not
e viewed as a comprehensive statement on competence in
hese areas.
.4. Purpose
he purpose of this document is to delineate the knowledge
ase and skills necessary for expertise in the care and
anagement of patients with advanced HF and heart
ransplantation. It is intended to be used by hospitals,
nstitutions, and credentialing bodies that must at times
istinguish specialists in the management of patients with
dvanced HF and heart transplantation from other well-
rained physicians who care for the majority of patients with
ess advanced forms of HF. The document is not meant to
imit physicians who care for patients with HF. The
ommittee recognizes that most patients with HF are
ared for by noncardiologists. This document attempts to
pecify the required knowledge base and skills required to
ompetently care for patients with advanced HF and
eart transplantation.
. Pathways to Competence
.1. Formal Training
he development of the specialist called the advanced HF
nd transplant cardiologist is related fundamentally to an
xpanding array of surgical, medical, and device-based
herapies that improve the quality and/or extend the lives of
atients with various cardiovascular diseases. The era of
T428 Francis et al. JACC Vol. 56, No. 5, 2010
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Task
Force Area Level
Minimal Number
of Procedures
Cumulative
Duration of
Training
(Months)
Minimal Cumulative
Number of Procedures Comments
1 Clinical cardiology 1 36
2 Electrocardiography 1
2
3500*†
3500
36 3500 *Can be taken throughout the training
program. †The committee strongly
recommends that cardiologists
achieve Level 2 training in ECG
interpretation.
Ambulatory monitoring 1
2
150*
75
150
225
*Can be taken throughout the training
program.
Exercise testing 1
2
200*
100
200
300
*Can be taken throughout the training
program.
3 Diagnostic
catheterization
1
2
100
200
4
8
100
300
Interventional
catheterization
3 250 20 550
4 Echocardiography 1 (75/150) 3 75/150
2 (75/150) 6 150/300
3 (150/450) 12 300/750
5 Nuclear cardiology 1 100 cases 2 100 cases
2 300 cases 4–6 300 cases
3 600 cases 12 600 cases
6 Electrophysiology, pacing,
and arrhythmias
1 20 2 10 temporary
pacemakers
10 DC cardioversions
2 100 6 100 pacemaker
interrogation/
reprogramming
3 300* prior procedure volume during
Level 1 and 2 training is
cumulative and counts towards
overall numbers recommended
for Level 3 training
12–24 150 EP cases
75 ablations
75 pacemaker/ICDs
*Can be taken throughout the training
program.
7 Research 1
2
3
6–12‡
24
24–36
‡Can be taken as part of 9 months of
required nonlaboratory clinical
practice rotation.
8 Heart failure and
transplantation
1
2
3
1‡§
6
12
‡Can be taken as part of 9 months of
required nonlaboratory clinical
practice rotation.
§It is assumed that trainees will
obtain additional training in heart
failure and preventive
cardiovascular medicine beyond the
1-month core training as part of the
experience during other clinical
months, such as consult services
and CCU.
9 Congenital heart disease 1
2
3
Core lectures‡
12
24
40 catheterizations
300 TTE cases
50 TEE cases
‡Can be taken as part of 9 months of
required nonlaboratory clinical
practice rotation.
10 Preventive cardiovascular
medicine
1
2
3
1‡§
6–12
12
‡Can be taken as part of 9 months of
required nonlaboratory clinical
practice rotation.
§It is assumed that trainees will
obtain additional training in
preventive cardiovascular medicine
beyond the 1-month core training
as part of the experience during
other clinical months, such as
consult services and CCU.
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July 27, 2010:424–53 Competence for Heart Failure and Transplantationasodilator-based regimens for HF began with publication
f the V-HeFT (Vasodilator-Heart Failure Trial) in June
986 (2). Heart transplantation was undertaken with re-
ewed enthusiasm in the same decade with introduction of
yclosporine-based immunosuppressive therapy (3,4). In
984, the U.S. Congress passed the National Transplant
ct (5), which facilitated procurement of donor hearts and
ncreased the availability of heart transplantation. Although
any clinicians caring for patients with HF are not cardi-
logists (6,7), this document addresses training pathways for
he advanced HF and transplant cardiologist, and includes
ot only patients with Stage D disease, but also patients
ith less advanced but more unique myocardial diseases
uch as infiltrative and hereditary cardiomyopathies.
COCATS 3 (Version 3 of the Adult Cardiovascular
edicine Core Cardiology Training Statement) has artic-
lated tiers of training in cardiology and its subspecialties
8). Training in HF, likewise, can be viewed in terms of 3
scending levels of intensity (1). Level 1 represents the basic
raining and competence that every cardiology fellowship
rainee must experience and demonstrate. Table 1 outlines
he scope of training in a 3-year cardiovascular fellowship at
evel 1, as well as the intensified experience for competence
n HF and the other subspecialties of cardiology. Many
evel 1 training components in cardiology are fundamental
o the experience for the advanced HF cardiologist. These
nclude the fundamentals of cardiovascular hemodynamics,
able 1. Continued
Task
Force Area Level
Minimal Number
of Procedures
11 Vascular medicine 1
Vascular medicine
specialist
Peripheral vascular
intervention
2
3
475 noninvasive vascular cases
100 diagnostic peripheral
angiograms, 50 peripheral
angioplasties/stents,
10 peripheral thrombolytic
infusions/thrombectomy
12 Cardiovascular magnetic
resonance
1
2
3
13 Computed tomography 1
2
3
eprinted from Beller et al. (8).
CCU indicates coronary care unit; CTA, computed tomography angiography; DC, direct
EE, transesophageal echocardiography; and TTE, transthoracic echocardiography.ardiac imaging, exercise cardiovascular physiology, acute eritical coronary care, and the perioperative care of patients
ndergoing cardiac surgery. Additional elements relevant to
he advanced HF subspecialty include arrhythmia manage-
ent, management of ischemic and valvular heart disease,
asic cardiovascular pharmacology, understanding of neu-
ohumoral activation, cardiomyocyte biology, and the phe-
otypical manifestations of cardiac dysfunction, including
F with dilated cardiomyopathy and HF with preserved
jection fraction.
Level 1 training introduces a number of important issues
ith respect to the management of patients with HF, includ-
ng the clinical trial evidence relevant to management of HF;
ndications for prescription of nonpharmacological or nonde-
ice treatment modalities in patients with HF; diet and activity
ecommendations; indications for cardiac transplantation; and
he evidence for differences in management and response to
herapy based on etiology, cardiac structure and function, age,
ender, ethnic background, and comorbidity.
Level 2 training involves intensified instruction and
xperience in HF-related activities, so the trainee can focus
ubsequent clinical effort on the evaluation and management
f patients with HF or on research. COCATS suggests that
his training should occur over approximately 6 months, and
ight encompass prolonged clinical experience in a HF
linic, hospital unit for HF patients, heart transplantation
rogram, or where mechanical circulatory assist device
MCAD) surgery is performed. Level 2 training should
umulative
uration of
Training
(Months)
Minimal Cumulative
Number of Procedures Comments
2* *Can be taken throughout the training
program.
12¶
12#
475 noninvasive
vascular cases
100 diagnostic
peripheral
angiograms,
50 peripheral
angioplasties/stents,
10 peripheral
thrombolytic
infusions/
thrombectomy
¶The prerequisite for Level 2 training
is Level 1 training in vascular
medicine.
¶In addition to all other clinical
requirements for Level 2 training.
#The prerequisite for Level 3 training
includes Level 1 training in vascular
medicine, and Level 1 and 2
training in diagnostic cardiac
catheterization. Requirements for
Level 3 training in peripheral
vascular intervention can be fulfilled
during a 4th year of interventional
training focused on peripheral
vascular intervention or concurrently
with cardiac interventional training.
1**
3–6
12
25 cases
150 cases
300 cases
**Can be taken as part of 7 months
of noninvasive imaging rotation.
1**
2
6
50 cases
150 CTA cases
300 CTA cases
**Can be taken as part of 7 months
of noninvasive imaging rotation.
; ECG, electrocardiogram; EP, electrophysiology; ICD, implantable cardioverter-defibrillator;C
Dxpose physicians to patients receiving an MCAD or heart
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Competence for Heart Failure and Transplantation July 27, 2010:424–53ransplant. One to 2 months of the 6 months should be
pent at an implanting center/transplant center if the parent
raining site does not implant MCADs or perform heart
ransplantation.
Level 3 training provides an opportunity to acquire the
ompetence required for physicians specializing in advanced
F and transplant cardiology. The necessary experience
ncludes advanced training in cardiac transplantation,
CADs, and HF disease management. Level 3 requires
ore than just a proficiency in the evaluation of patients
ndergoing MCADs or cardiac transplantation. Physicians
eed to acquire the skills to manage these patients periop-
ratively and post-ventricular assist device (VAD) implant
s well as after cardiac transplantation. The training must
ncompass the use of echocardiography to facilitate adjust-
ent of pulsatile and nonpulsatile pumps. In addition, the
hysician needs to have an intimate knowledge of the
omplications in patients following cardiac transplantation
ncluding rejection, infection, malignancy, vasculopathy,
nd the adverse risks of immunosuppressant therapies.
any cardiology programs offer sufficient exposure in the
evel 3 curriculum to qualify the trainee for the United
etwork of Organ Sharing (UNOS) designation of heart
ransplantation physician (see the following text). Advanced
raining requires demonstration of proficiency in the man-
gement of challenging HF patient cohorts, including those
equiring chronic inotropic drug infusion support or
ospice-based end-of-life care, and those undergoing eval-
ation for cardiac transplantation or MCADs.
The writing committee believes that competence in
dvanced HF requires training in selecting patients for
ardiac transplantation, and in all other aspects of posttrans-
lantation care. This is reflected in the COCATS docu-
ent (8), and in the criteria for certification in the secondary
ubspecialty of advanced HF and transplantation cardiology
pproved by the American Board of Medical Specialties and
he ABIM. Accordingly, if training in cardiac transplanta-
ion is not offered at the primary training institution,
xperience should be sought during outside rotations at an
nstitution that performs at least 10 heart transplants per
ear. Please note, in order to become a certified UNOS-
ransplant cardiologist, the requirements involve a higher
umber of transplant patients (9). We acknowledge that a
umber of highly competent HF specialists have practiced
nd published research findings during the early stages of
volution of this secondary subspecialty, when heart trans-
lantation surgery was uncommon. As this field moves
orward, however, the HF specialist will be expected to
evelop competence in all validated forms of therapy for
atients with advanced HF and heart transplantation.
.2. ABIM Certification
he American Board of Medical Specialties and the ABIM
pproved certification of adult cardiologists in the secondary
ubspecialty of advanced HF and transplant cardiology.
equirements for fellowship training in advanced HF and transplantation cardiology are concordant with those out-
ined for the Level 3 training in COCATS (8). A physician
ay apply for certification by the following pathway:
. Complete a 3-year cardiovascular fellowship to establish
Board eligibility in the medical specialty of cardiovascu-
lar diseases
. Complete a 1-year fellowship in advanced HF and
transplant
. Successfully complete the certifying examination of the
ABIM
.3. Alternative Pathways
ardiologists who have completed general cardiology train-
ng and have focused the majority of their professional effort
n the care and management of patients with HF may apply
or ABIM certification in the secondary subspecialty of
dvanced HF and transplant cardiology. Eligibility for
ertification along this alternative pathway requires attesta-
ion by professional colleagues and/or the division chair to
heir experience and competence in HF, as determined by
he ABIM. Further details are to be worked out, but the
pplicant is expected to be eligible to take the certifying
xamination. This alternative pathway will be available for
everal years after initiation of the certifying examination in
dvanced HF and transplant cardiology. D.O. cardiologists
ith appropriate advanced HF and transplant cardiology
raining may, by virtue of their internal medicine certifica-
ion, not be eligible to take the ABIM examination. If their
raining has met all of the herein-described criteria, those
ardiologists should be considered no less qualified.
.3.1. Pediatric Advanced HF and Transplantation
n parallel with the adult experience, heart transplantation
n children was first performed in the late 1970s as a therapy
or both end-stage congenital heart disease and cardiomy-
pathy. Experience with pediatric heart transplantation
rew exponentially during the 1980s and early 1990s; since
992, however, the number of pediatric heart transplanta-
ion procedures has remained stable at 375 to 400 per year
ecause of limited donor availability (10). Between 2004
nd 2006, 17 centers in the United States performed more
han 10 heart transplant procedures per year in children.
Given improved results with medical and device-based
herapies reported in children less than 18 years of age
11,12), the need has grown for pediatric cardiologists with
ubspecialty training in advanced HF and transplantation.
he management of children with cardiomyopathy, HF,
nd transplantation is included in the core knowledge base
f the current ACCF/AHA/ACP recommendations for
raining in general pediatric cardiology; however, specific
ompetence criteria are not provided (13). The small num-
er of pediatric cardiology training programs with active
ediatric heart transplantation programs limits the first-
and exposure of many general pediatric cardiology trainees
o the care of children with advanced HF undergoing heart
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July 27, 2010:424–53 Competence for Heart Failure and Transplantationransplantation. Although no formal process exists for
ertification in pediatric advanced HF and transplantation, a
mall number of pediatric heart transplant centers offer
ourth-year fellowships with specific training in HF and
eart transplantation.
Many of the competencies for the adult HF specialist
etailed in this document are applicable to the pediatric HF
pecialist. The underlying causes of advanced HF in the
ediatric age range include genetic, metabolic, idiopathic
nd acquired cardiomyopathies, congenital heart disease,
nd rare instances of ischemic heart disease. A comprehen-
ive statement of competencies for the pediatric HF spe-
ialist is beyond the scope of this document; however, some
eneral competencies are outlined in the following section:
• Knowledge of the manifestations of HF in children
and an ability to assess HF severity using medical
history, physical examination, genetic testing, biomar-
kers, imaging modalities, exercise stress testing, and
hemodynamic measurements
• Expertise in the evaluation and management of ad-
vanced HF and transplantation in the patient with
congenital heart disease
• Understanding of age-related differences in the phar-
macokinetics and pharmacodynamics of medications
used to treat advanced HF in children
• Ability to evaluate the indications, risks, benefits, and
limitations of ICD placement, cardiac resynchroniza-
tion therapy (CRT), and mechanical assist devices in
the pediatric size and age range
• Understanding of the indications for heart transplant
in specific age groups and diagnostic categories
• Understanding of the age-related differences in the
pharmacokinetics and pharmacodynamics of immuno-
suppressive medications in children
• Familiarity with the infectious disease risks of immu-
nosuppression in the pediatric age range
• Understanding of the neurodevelopmental and psy-
chosocial impact of HF and transplant on the child
and family and a ability to coordinate the services
needed to provide the appropriate interventions
• Expertise in palliative and end-of-life care in the
pediatric population
.3.2. Pathways to Establishing Competence in
ediatric Advanced HF and Transplantation
he pediatric HF specialist should be board-eligible to
btain certification in pediatric cardiology from the Amer-
can Board of Pediatrics Sub-Board of Cardiology and have
ompleted an additional year of fellowship at a pediatric
ransplant center or have focused the majority of his or her
rofessional efforts on the care and management of children
ith advanced HF.
Additional evidence of competence includes designation
s a primary heart transplant physician by the Organ
rocurement Transplant Network (OPTN)/UNOS Mem- iership and Professional Standards Committee. For a pe-
iatric HF specialist to function as the primary heart
ransplant physician, she or he must demonstrate to the
atisfaction of the Committee and Board of Directors that
is/her training and/or experience in the care of heart
ransplant patients is equivalent to that described in the
equirements outlined for adult heart transplant physicians.
n addition, the physician must demonstrate maintenance of
atisfactory knowledge through direct involvement in all
spects of heart transplantation and patient care within the
ast 2 years (14).
.4. Pathway to Competence in
ardiac Transplantation
NOS has developed standards and established a pathway
f training for designation of cardiologists as specialists in
ardiac transplantation. It is expected that cardiologists can
cquire this experience and competence during 1 year as a
ellow in advanced HF and transplantation. Alternatively,
ardiologists may acquire the experience and develop com-
etence though clinical practice.
An advanced HF and transplant cardiologist should hold
n M.D., D.O., or equivalent degree from another country,
ave a valid license to practice medicine in his or her state,
nd be certified by the Cardiovascular Disease ABIM,
merican Osteopathic Board of Internal Medicine, or its
oreign equivalent. The applicant shall provide a letter from
he chair of the credentialing committee of the hospital
here the applicant practices stating that he or she is a
ember of the cardiology staff in good standing. The
raining/experience requirement for qualification as a heart
ransplant physician can be met through a variety of
athways summarized in the UNOS Bylaws (9).
. Components of Competence Required for
he Management of Patients With HF
.1. Cognitive Knowledge Base
ompetence in advanced HF and transplantation requires a
road base of knowledge in internal medicine, especially as
t pertains to organ systems that are often affected by HF.
he HF specialist recognizes the risk factors associated with
he development of HF such as hypertension, diabetes
ellitus, and coronary artery disease and understands the
reventive measures necessary to control these risk factors.
trategies used to prevent HF include control of blood
ressure, promotion of physical fitness, smoking cessation,
reatment of hyperlipidemia, and maintenance of ideal body
eight and healthy lifestyle. It is important that the HF
pecialist have a penetrating understanding of organ phys-
ology, pathophysiology of HF, cardiomyopathy, pharma-
ology, electrophysiology, performance measures, and many
ther elements as they pertain to the care of patients with
dvanced HF and/or heart transplantation. Rigorous train-
ng in general clinical cardiology with emphasis on areas
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Competence for Heart Failure and Transplantation July 27, 2010:424–53ost pertinent to the diagnosis and management of patients
ith HF is an important requirement in the development of
ompetence in the care of these complex patients. This
resumes cost-consciousness care and history taking. As a
ractical matter, it would be extremely difficult for an
ndividual who has not received accredited training in
nternal medicine and cardiovascular disease to acquire this
nowledge and experience.
A key skill that the HF specialist should have is the ability
o administer and interpret formal quality-of-life assess-
ent. The HF specialist should be able to assess quality of
are and should be able to adopt mechanisms to ensure
ontinuous quality improvement. A detailed knowledge of HF
uidelines is essential. In addition, the HF specialist should
ave a basic knowledge of clinical trial design and should be
ble to analyze and understand new scientific data in the
ontext of the care of advance HF and heart transplantation.
.2. Knowledge Base in Cardiovascular Biology
nd Physiology
he specialist in advanced HF should have a thorough
nderstanding of normal cardiovascular physiology and
athophysiology. Important components are as follows:
• Excitation–contraction coupling and the contractile
properties of the cardiomyocyte
• Ventricular systolic and diastolic function
• Ventricular structure, geometry, and remodeling, in-
cluding extracellular matrix biology
• Physiology and pathophysiology of cardiomyopathy,
including genetics, arrhythmias, biomarkers, exercise
physiology, and the different pathophysiology of re-
strictive cardiomyopathy, dilated cardiomyopathy, and
hypertrophic cardiomyopathy
• Physiological modulation of cardiomyocyte and ven-
tricular function
• Physiology and pathophysiology of the peripheral and
pulmonary vasculature, including endothelial function
and dysfunction
• Pathophysiology of coronary allograft vasculopathy
• Neurohumoral control of the heart and circulation and
alterations in patients with HF, including the sympa-
thetic and parasympathetic nervous systems, the renin-
angiotensin-aldosterone systems and the natriuretic
peptides
• Effects of vasoactive and inflammatory cytokines
• Hypercoagulable states and risks of arterial and venous
thromboembolic complications
.3. Technical Skills
ome technical skills are required for competence in ad-
anced HF and transplantation beyond those acquired as
art of general cardiology training. In many medical centers,
F specialists perform cardiopulmonary exercise testing,
ight-heart catheterization, and myocardial biopsy proce-
ures. Management of assist devices, interrogation of ICDs,
nd interpretation of CRT data are considered “technical” dy some cardiologists. The specialist caring for patients with
dvanced HF must demonstrate a thorough understanding
f hemodynamic measurements obtained by right-heart
atheterization. Familiarity with normal, abnormal, and
rtifactual waveforms and measurements of pressure and
ow may be critical in determining the correct diagnosis,
ourse of treatment, and response to therapy in this patient
opulation. There should also be familiarity with vasodilator
rug testing for the diagnosis and treatment of pulmonary
rterial hypertension. HF specialists should understand the
ndications for endomyocardial biopsy and knowledge of
hen special preparation of the sample is required (e.g.,
pecialized handling for suspected amyloid infiltration).
.4. Referral for Cardiac Surgery
he HF specialist should be able to identify potentially
eversible causes of HF that are amenable to surgical
ntervention. The HF specialist should have a thorough
nderstanding of surgical interventions available for patients
ith advanced HF, including myocardial revascularization
ith coronary bypass surgery, valvular repair and replace-
ent, myectomy, pericardiectomy, ventricular restoration
rocedures, and the use of mechanical circulatory support as
bridge to recovery, a destination therapy (i.e., permanent
evice implantation without plans for heart transplanta-
ion), and a bridge to heart transplantation (15–19). Surgical
herapies for the treatment of advanced HF are associated
ith fewer evidence-based recommendations from random-
zed trials to guide decisions with respect to patient selection
nd comparison of benefits and risks of alternative strate-
ies. Several of these surgical therapies are currently under-
oing evaluation in rigorous trials, and HF specialists are
xpected to keep abreast of results and recommendations
hrough continuous education (20). The HF specialist must
ncorporate the best available evidence with respect to
otential benefit and risk in the context of the individual
atient, and must be able to critically evaluate novel surgical
herapies.
This principle is especially important in assessing patients
ith advanced HF who have comorbidities that affect the
stimation of benefit and risk associated with surgical
ntervention. Accordingly, the specialist should be able to
dentify, assess, and treat comorbid conditions in patients
ith advanced HF being considered for cardiac surgical
ntervention. Among the most frequently encountered of
hese comorbidities are poor functional capacity, advanced
ge, cognitive impairment, renal dysfunction, hepatic dys-
unction, coagulopathy, pulmonary hypertension, diabetes,
alnutrition, cachexia, respiratory disorders, anemia, al-
ered immune status, and psychological depression (21–25).
The evaluation of patients with advanced HF for surgical
herapy may require diagnostic studies beyond those used in
ess severely ill patients. The HF specialist should have
nowledge of diagnostic modalities used to define the
resence and extent of coronary disease and assess myocar-
ial ischemia and viability. The specialist should be able to
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July 27, 2010:424–53 Competence for Heart Failure and Transplantationdentify the presence and severity of valvular, congenital,
nd pericardial disease that compromises cardiac function.
ypically, patients with advanced HF require a more
horough evaluation to identify potentially reversible causes
f HF. Examples include the patient with ischemic heart
isease in whom identification of hibernating myocardium
s critical to the decision to recommend myocardial revas-
ularization and the patient with aortic stenosis, severe left
entricular dysfunction, and a low transvalvular gradient
ho may benefit from aortic valve replacement (26,27). The
F specialist should be able to design a strategy that
omprises the use of multiple imaging modalities (e.g.,
obutamine stress perfusion and metabolic imaging by
ositron emission tomography, and assessment of cell mem-
rane integrity and contractile reserve by either thallium or
echnetium-99m Tc-sestamibi single photon emission com-
uted tomography) if necessary. The HF specialist must be
ble to integrate information from established and emerging
odalities, including cardiovascular magnetic resonance.
he HF specialist should be able to interpret results of
ardiovascular magnetic resonance obtained to detect myo-
ardial viability and enhance diagnostic capabilities in the
valuation and management of valvular, congenital, and
ericardial disease. The HF specialist must also be able to
mploy the results of exercise testing for determination of
eak exercise oxygen consumption, right-heart catheteriza-
ion, and myocardial biopsy to formulate a management
trategy and choose between surgical and medical therapy or
etween different types of surgical intervention (e.g., coro-
ary bypass grafting versus heart transplantation).
It is important that the HF specialist, in collaboration
ith other specialists and an experienced surgical team,
hould be competent in devising a coordinated care plan to
ddress the overall health of the patient and mitigate
erioperative risk (28). Thus, the HF specialist must recog-
ize factors associated with perioperative morbidity and
ortality and be familiar with strategies for treating these
onditions. The HF specialist should have specific knowl-
dge of perioperative management of anticoagulation, par-
nteral administration of cardiac and noncardiac drugs,
articularly those required for hemodynamic support of
ritically ill patients, including vasopressor, vasodilator, and
notropic drugs. The HF specialist should have a thorough
nderstanding of temporary mechanical circulatory support
evices that may be required for patients with decompen-
ated HF who have become refractory to standard therapy
nd require optimization of clinical status prior to surgical
ntervention. The HF specialist must be able to recognize
ostoperative complications, including cardiac arrhythmias,
yocardial ischemia, cardiac tamponade, and other condi-
ions that adversely affect cardiac function.
.5. Referral of Patients With Advanced HF for
oncardiac Surgery
lthough there have been many studies of the risk of
schemic events in patients with and without coronaryisease undergoing noncardiac surgery, few systematic stud-
es have addressed the risks of noncardiac surgery in patients
ith HF, much less in those with advanced HF (29).
The specialist in advanced HF should be thoroughly
amiliar with published guidelines on reducing the risk of
oronary events in patients undergoing noncardiac surgery.
he lack of definitive evidence specific to patients with HF
equires that the specialist have the judgment to estimate
he relative risks and benefits of specific surgical procedures
n patients with advanced HF.
The HF specialist must be able to assess the importance
f the planned surgical procedure and its relationship to the
atient’s long-term well-being from both the patient’s
erspective and in the context of estimated risks from both
nown and unanticipated causes. The HF specialist should
e able to assess the risks derived from the surgery-specific
nd patient-specific components listed below to provide
uidance to the surgeon, anesthesiologist, and other care-
ivers throughout the perioperative period.
.5.1. Surgery-Specific Components
• Elective or urgent timing of intervention
• Anticipated level of hemodynamic stress during anes-
thesia, surgery, and the postoperative period
• The experience of the surgeon and anesthesiologist in
patients with advanced HF
.5.2. Patient-Specific Components
• Etiology of HF
• Severity of underlying cardiac dysfunction
• Status and stability of HF compensation
• Presence and severity of comorbidities (e.g., renal,
pulmonary, or hepatic disease)
• The patient’s understanding of risks and benefits
• Advance directives in the event of complications or
unfavorable outcome
.5.3. Perioperative Management
f a decision is made to proceed with surgery, the advanced
F specialist must be competent to provide expert assis-
ance in management during the perioperative period, with
articular attention to the following potential needs:
• Additional diagnostic testing (e.g., to assess cardiac
function or the risk of myocardial ischemia)
• Preoperative stabilization, including revascularization,
in relation to the timing of surgery
• Perioperative hemodynamic monitoring
• Management of medications throughout the perioper-
ative period, including anticoagulation and adminis-
tration of medications by parenteral routes
• Indications for intravenous diuretic or inotropic support
• Mechanical circulatory support
• Prophylaxis against or management of disturbances of
cardiac rate or rhythm (e.g., accelerated ventricular rate
with atrial fibrillation)
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Competence for Heart Failure and Transplantation July 27, 2010:424–53able 2. Schedule of Examinations in Candidates for Cardiac Transplantation
Test
Repeat
Baseline 3 Months 6 Months 9 Months
12 Months
(and Yearly)
omplete H & P X
Follow-up assessment X X X X
Weight/BMI X X X X X
mmunocompatibility
ABO X
Repeat ABO X
HLA tissue typing Only at transplant
PRA and flow cytometry X
● 10% Every 1–2 months
● VAD Every 1–2 months
● Transfusion 2 weeks after
transfusion and then
9 months  6 months
ssessment of heart failure severity
Cardiopulmonary exercise test with RER X X
Echocardiogram X X
Right heart catheter (vasodilator challenge as indicated) X X X
ECG X X
valuation of multiorgan function
Routine lab work (BMP, CBC, LFT) X X X X X
PT/INR More frequent per protocol if on VAD or warfarin X X X X X
Urinalysis X X X X X
GFR (MDRD quadratic equation) X X X X X
Unlimited urine sample for protein excretion X X X X X
PFT with arterial blood gasses X
CXR (PA and lateral) X X
Abdominal ultrasound X
Carotid Doppler (if indicated or 50 y) X
ABI (if indicated or 50 y) X
DEXA scan (if indicated or 50 y) X
Dental examination X X
Ophthalmologic examination (if diabetic) X X
nfectious serology and vaccination
Hep B surface Ag X
Hep B surface Ab X
Hep B core Ab X
Hep C Ab X
HIV X
RPR X
HSV IgG X
CMV IgG X
Toxoplasmosis IgG X
EBV IgG X
Varicella IgG X
PPD X
Flu shot (q 1 y) X
Pneumovax (q 5 y) X
Hep B immunizations: 1_2_3 X
Hep B surface Ab (immunity) 6 weeks after third
immunization
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July 27, 2010:424–53 Competence for Heart Failure and Transplantation• Management of postoperative problems related to
changes in cardiac loading conditions and intravascular
volume
. Components of Competence Required
or Management of Patients With
eart Transplantation or Mechanical
irculatory Assist Devices
.1. Evaluation of Patients for
ardiac Transplantation
ardiac transplantation and destination VAD placement
re the only established surgical treatments for advanced,
nd-stage HF. Improvement in other therapeutic options
vailable for patients with HF and a persistent shortage of
onor hearts make it critical that the HF specialist be able
o identify patients with poor prognosis who could most
enefit from transplantation. The AHA statement on “Se-
ection and Treatment of Candidates for Heart Transplan-
ation” specifies that a multidisciplinary team with expertise
n HF should evaluate candidates for cardiac transplantation
30). The HF specialist should have the skills to manage the
eam and be able to reevaluate patients periodically and
onitor and adjust therapy as outlined in Table 2. In most
nstances, the “team” caring for these patients includes HF
ransplant specialists, cardiothoracic surgeons, internists,
urse coordinators, nurses, fellows, social workers, psychol-
gists, and financial managers. The HF specialist should
nteract with other physicians in such a way so as to facilitate
ommunication with the families and the patient. This
eans working closely with internists, primary care physi-
ians, and other referring doctors. Additionally, the HF
able 2. Continued
Test Basel
reventive and malignancy
Stool for occult blood  3 X
Colonoscopy (if indicated or 50 y) X
Mammography (if indicated or 40 y) X
Gyn/Pap (if indicated 18 y sexually active) X
PSA and digital rectal exam (men 50 y) X
eneral consultations
Social work X
Psychiatry X
Financial X
Neuro/psych (if applicable) X
eprinted with permission from Mehra et al. (32).
Ab indicates antibody; ABI, ankle brachial index; ABO, blood type ABO; Ag, antigen; BMI, body
hest x-ray; DEXA, dual energy x-ray absorptiometry; EBV, Epstein-Barr virus; ECG, electrocardiog
epatitis C; H & P, history and physical; HLA, human leukocyte antigen; HSV, herpes sim
eurological/psychological; PA, posterior/anterior; PT/INR, prothrombin time-international norm
ntibodies; PSA, prostate-specific antigen test; RER, respiratory exchange ratio; RPR, rapid plaspecialist should include these physicians in regular peer tducation exercises in order to facilitate interaction and
ommunication.
The COCATS Task Force Section 8 on “Training in
eart Failure” specifies that the clinician competent in
dvanced HF and Transplantation should be familiar with
he indications for transplantation, criteria for the evalua-
ion of potential candidates, and techniques for managing
atients as a member of the team of transplant professionals
1). The HF specialist should be very familiar with the most
ecent ACC/AHA guidelines for the management of
hronic HF, which recommend that eligible patients with
tage D HF be referred for cardiac transplantation (Class I,
evel of Evidence: B) (28), as well as the HFSA guidelines
31) and ISHLT guidelines (32,33). The HF specialist
hould be able to assess prognosis and advise both patient
nd family about management choices, including transplan-
ation and mechanical devices.
The HF specialist should be able to search for a poten-
ially reversible etiology of HF that may be amenable to
pecific medical or surgical intervention (34) and should be
ble to identify those patients who either fail to improve or
ave contraindications to these treatment modalities. The
F specialist should be thoroughly versed in the current
ndications for cardiac transplantation, shown in Table 3,
hich focus on patients who are severely limited and who
ay need continuous inotropic therapy or a mechanical
evice for survival (28).
Specific skills are necessary for competence in the evalu-
tion of candidates for cardiac transplantation. Interpreta-
ion of cardiopulmonary testing for peak oxygen uptake
VO2) is an important skill to help in patient selection, but
atient selection should not be based solely on functional
apacity. Appropriate integration of the peak VO2 informa-
Repeat
3 Months 6 Months 9 Months
12 Months
(and Yearly)
X
X
X
X
index; BMP, basal metabolic pattern; CBC, complete blood count; CMV, cytomegalovirus; CXR,
FR, glomerular filtrate rate; Gyn/Pap, gynological/Papanicolau test; Hep B, hepatitis B; Hep C,
irus; LFT, liver function test; MDRD, Modification of Diet in Renal Disease; Neuro/psych,
atio testing; PFT, pulmonary function test; PPD, purified protein derivative; PRA, panel reactive
gin; and VAD, ventricular assist device.ine
mass
ram; G
plex vion with other clinical data is an essential skill set. Inter-
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Competence for Heart Failure and Transplantation July 27, 2010:424–53retation of hemodynamic values (Table 4) and assessment
f the reversibility of pulmonary hypertension are also
mportant skill sets of the HF specialist involved with
retransplant evaluation (32). Other parameters are also
ertinent, and the evaluation process requires the HF
pecialist to review and integrate the information listed in
able 2 into the evaluation process and collaborate with
ther members of the multidisciplinary HF transplantation
eam to determine the need for listing (32).
.2. Perioperative Management of Patients
ndergoing Heart Transplantation
he immediate postoperative care of the cardiac transplant
ecipient requires the HF specialist to be knowledgeable
egarding the problems that may arise and be able to
oordinate patient care with other members of the team,
ncluding anesthesiologists, critical care physicians, and
urgeons. If the development of competence in the care of
atients with heart transplantation is not available at the
rimary training site, experience in cardiac transplantation
hould be obtained during rotations at an institution where
ore than 10 transplants are performed yearly. The writing
ommittee recognizes that some flexibility will be needed in
ndividual cases regarding this requirement for competence.
The development of competence in the evaluation and
are of patients with heart transplant requires that the HF
pecialist understand the physiology of the denervated heart
nd the differences in therapeutic response to medications in
able 3. Indications for Cardiac Transplantation
Absolute Indications
or hemodynamic compromise due to HF
Refractory cardiogenic shock
Documented dependence on IV inotropic support to maintain adequate organ
Peak VO2 less than 10 mL per kg per min with achievement of anaerobic met
evere symptoms of ischemia that consistently limit routine activity and are not
ecurrent symptomatic ventricular arrhythmias refractory to all therapeutic mod
Relative
eak VO2 11 to 14 mL per kg per min (or 55% predicted) and major limitation o
ecurrent unstable ischemia not amenable to other intervention
ecurrent instability of fluid balance/renal function not due to patient noncomp
Insufficie
ow left ventricular ejection fraction
istory of functional class III or IV symptoms of HF
eak VO2 greater than 15 mL per kg per min (and greater than 55% predicted)
eprinted from Hunt et al. (28).
HF indicates heart failure; IV, intravenous; and VO2, oxygen consumption per unit time
able 4. Hemodynamic Criteria for Evaluation of Candidates fo
Pulmonary artery hypertension and elevated PVR should be considered as a re
the PVRI is 6 or the TPG exceeds 16 to 20 mm Hg
If the PAS exceeds 60 mm Hg in conjunction with any 1 of the preceding 3 var
If the PVR can be reduced to 2.5 with a vasodilator but the systolic blood pre
mortality after cardiac transplantationalculations: transpulmonary gradient (TPG [PAMP PCWP]); pulmonary vascular resistance (PVR [TPG/C
rom Mehra et al. (32).atients with native heart disease and following transplan-
ation. Recognition of causes of early mortality, such as
cute graft rejection and infection, and identification and
anagement of right ventricular failure and pulmonary
ypertension are also important measures of competence of
he HF specialist. In addition, the HF specialist should be
ompetent in early postoperative management of patients
ollowing heart transplantation, including the need for
mplantation of a right-VAD (35). The HF specialist
hould have experience with and knowledge of pre- and
ostoperative nutritional support and rehabilitation of the
atient following heart transplantation.
UNOS clearly delineates the requirements of a cardiac
ransplant physician as part of a UNOS-certified transplant
rogram (9). These are reinforced in the COCATS Task
orce 8 document (8).
.3. Posttransplant Care
s the survival of patients undergoing cardiac transplanta-
ion improves, many return to the community and receive
are from local cardiologists. Successful management, there-
ore, extends beyond the initial concern about rejection. The
F specialist should be familiar with ISHLT Registry data
36) that indicate that malignancy and coronary artery
asculopathy (CAV) are the major causes of death in
ost-heart transplant patients. This is particularly important
years following transplantation, when the frequency of
yocardial biopsy diminishes and patients typically receive
ppropriate Patients
ion
m
able to coronary artery bypass surgery or percutaneous coronary intervention
ations
patient’s daily activities
with medical regimen
ications
t other indications
diac Transplantation
contraindication to cardiac transplantation when the PVR is 5 Wood units or
, the risk of right heart failure and early death is increased
falls 85 mm Hg, the patient remains at high risk of right heart failure andin A
perfus
abolis
amen
alities
Indic
f the
liance
nt Ind
withour Car
lative
iables
ssureO Wood units]); pulmonary vascular resistance index (PVRI [TPG/CI]). Reprinted with permission
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July 27, 2010:424–53 Competence for Heart Failure and Transplantationare outside the transplant center (37,38). Most heart
ransplant patients continue to receive at least some of their
are from a transplant center. HF specialists should be com-
etent to provide ongoing care even late after transplant.
Long-term immunosuppressive therapy may potentiate
he emergence of hypertension, hypercholesterolemia, renal
ysfunction, glucose intolerance, osteoporosis, malignancy,
nd other adverse conditions (37). Competence in post-
ransplantation patient care requires understanding of the
isk factors that threaten the graft and compromise patient
urvival, and knowledge of the often complex therapeutic
egimens used with this patient group (39). There has been
suggestion that clinical experience in the care of no fewer
han 30 posttransplant patients, at least 5 of whom are
ollowed immediately following the transplantation surgery
s a reasonable goal in the development of competence in the
are of the posttransplant patient (39).
As posttransplant antirejection therapy has advanced
rom cyclosporine-based regimens to combinations of im-
unosuppressive agents, the HF specialist should have
n-depth knowledge of the pharmacology of various immu-
osuppressive therapeutic agents and combinations, includ-
ng pharmacokinetics, drug–drug interactions and contra-
ndications, and dose adjustment based on measurement of
rug levels to achieve the desired therapeutic effect and
void toxicity (39). The HF specialist should have compe-
ence regarding immune monitoring of the cardiac allograft.
amiliarity with the types of rejection (cellular and
ntibody-mediated) and their diagnostic features on
ndomycardial biopsy and serologic of antibody-mediated
ejection and allograft dysfunction is required as is an
nderstanding of the usefulness and limitation of the
ndomyocardial biopsy for the diagnosis and follow-up of
ejection. The HF specialist must be able to integrate the
esults of these diagnostic modalities into the plan for the
arly and long-term treatment of the different types of
ejection (40–43). The HF specialist must be familiar with
he risks of opportunistic infections and therefore must be
ompetent in the diagnosis and treatment of these condi-
ions. This includes knowledge of both prophylaxis and
reatment of associated infectious diseases in patients that
re immunosuppressed (44).
The risk of developing malignancy is increased among
ransplant recipients, requiring competence in providing
ducation regarding routine malignancy awareness and sys-
ematic cancer surveillance by colonoscopy, mammography,
ynecological or prostate examinations, periodic skin exam-
nation, and serological testing (e.g., measurement of the
erum prostate-specific antigen) familiar to the HF special-
st. If a malignancy occurs, the HF specialist should be able
o obtain consultative support in oncology (45).
Coronary allograft vasculopathy increases in severity over
ime following heart transplantation. The HF specialist
hould be able to detect CAV using noninvasive and
ometimes invasive testing and should be knowledgeable begarding various treatments. As patients return to their
aily activities, the HF specialist should have knowledge of
he physiology of the denervated heart in response to
xercise and be able to make knowledgeable recommenda-
ions regarding the type, frequency, and intensity of physical
ctivity the patient can pursue. The HF specialist should be
amiliar with the physiologic and immunologic changes that
ccur during pregnancy, especially as they affect pregnancy
n the HF and transplant patient.
.4. Mechanical Support of the Patient With
dvanced HF
he HF specialist should have the ability to synthesize a
ongitudinal plan that accounts for both the short-term need
o resuscitate and stabilize the patient. The HF specialist
hould recognize the need for long-term support in patients
ith progressive circulatory impairment despite appropriate
harmacological, electrical, catheter-based, and surgical in-
erventions. Thus, the specialist should have a thorough
nderstanding of prognosis and be fully versed in applica-
ion of conventional evidenced-based therapies prior to use
f mechanical support, including neurohumoral blockade,
evascularization, valve repair, ICDs, CRT, and such
merging procedures as ventricular aneurysmectomy or
entricular remodeling. Specialists in this field must be
amiliar with a growing list of devices and surgical interven-
ions. The nuances are complex and the initiation of this
ype of therapy requires surgical consultation and appropri-
te timing of referral to multidisciplinary teams. Compe-
ence implies understanding of indications and contraindi-
ations, timing of referral, and potential complications. If
he patient deteriorates rapidly (over minutes to days), the
F specialist should be aware of the indications and
ontraindications of the various modalities that can tempo-
arily reverse cardiogenic shock, such as an intra-aortic
alloon pump, transseptal left ventricular assist device
LVAD), or extracorporeal cardiopulmonary bypass. The
F specialist should also understand the natural history and
otential for recovery following acute HF in situations such
s acute myocardial infarction, peripartum cardiomyopathy,
nd fulminant myocarditis (46 – 48). In patients with
arked cardiac dysfunction that persists despite temporary
upport, the HF specialist must be able to determine the
ndications for long-term mechanical support, cardiac trans-
lantation, or withdrawal of support and palliative care.
lthough surgical implantation of an LVAD is the most
ommon type of mechanical support for chronic HF (49),
nowledge of biventricular or total artificial heart support is
equired, including an understanding of certain technical
eatures and their relative strengths and weaknesses (50,51).
he HF specialist should have experience with pulsatile
ersus axial/continuous flow devices (18,52–54), intracorpo-
eal versus extracorporeal support, and left ventricular versus
iventricular or total artificial heart support. Programming
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Competence for Heart Failure and Transplantation July 27, 2010:424–53nd trouble-shooting devices are useful skills but are not
ritically necessary if other team members are able to
erform these procedures.
Whereas acute decompensated HF is often apparent, the
radual progression of chronic HF from ACCF/AHA Stage
to Stage D (28) may be subtle. Cognitive skills are therefore
equired to determine when mechanical support is indicated
or advanced chronic HF (18) before the patient has become
oo ill to benefit. In this regard, therapeutic decision making
verlaps and parallels that for cardiac transplantation.
Multidisciplinary teams are required that allow close collab-
ration between cardiologists, medical specialists, and cardiac
urgeons. The HF specialist must be participatory in managing
hese teams. Adverse postoperative outcomes are related to the
everity of preoperative noncardiac organ dysfunction (37,55).
he HF specialist should be familiar with the need to evaluate
ight ventricular function and associated tricuspid regurgitation
rior to placement of a LVAD. Because the postoperative
anagement of the LVAD and cardiac transplant patient is
ocused on right ventricular management, the HF specialist
hould be skilled in the management of right ventricular
ailure. Compared with successful cardiac transplantation, ex-
rcise capacity is less following chronic outpatient mechanical
upport (56,57) and the patient’s daily concerns are typically
reater (e.g., battery exchange or recharging, driveline mainte-
ance). The HF specialist should be able to interpret the results
f exercise testing following LVAD placement and make
ctivity level recommendations.
Mechanical support can be applied short-term in an
ndividual patient as a bridge to transplantation or can be
pplied long-term as in destination therapy. For example, if
patient with myocardial infarction and cardiogenic shock
xperiences a cardiac arrest that requires a prolonged resus-
itation, the HF specialist would know that percutaneous
echanical support could precede a potential LVAD until
eurologic status is determined. If an LVAD is subse-
uently implanted, the patient’s candidacy for transplanta-
ion versus discharge and long-term LVAD maintenance
herapy (i.e., destination therapy) must be considered. This
equires experience, skill, and judgment.
The HF specialist should be able to thoroughly inventory
he risks of continued HF therapy for individual patients
ompared with their ability to tolerate surgery. The HF
pecialist should be able to assess the prognosis of HF on
he basis of symptoms, clinical events, physical findings, and
aboratory and hemodynamic data—including measure-
ents of oxygen consumption during exercise testing (58).
isk factors for LVAD placement, including hemodynamic,
ematological, hepatic, renal, nutritional, and neuropsychi-
tric aspects, should be familiar to the HF specialist (55).
he HF specialist should be able to assess patient prefer-
nces related to quality of life and survival and coordinate
he decision-making process among the referring physician,
he family, and the patient. o.5. Perioperative Management of Patients
equiring Mechanical Devices
ecause chronic mechanical support usually involves an
VAD (49), the HF specialist should be knowledgeable
bout LVAD-related cardiac physiology at rest and during
xercise (57,59,60), including the interpretation of hemo-
ynamic data and responses to pharmacological manipula-
ion. Unique to mechanical support is interpretation of
VAD console readings and driveline assessment.
Complications following LVAD implantation should be
ecognized on the basis of immediate, recent, and long-term
ostoperative time periods. The HF specialist should be
nowledgeable regarding the following:
• Mechanical problems related to the LVAD, valve
conduit, right ventricular dysfunction or ischemia,
tricuspid regurgitation, aortic regurgitation with
shunting of LVAD output, pulmonary vascular resis-
tance, systemic vascular resistance, and patent foramen
ovale with hypoxemia (61,62)
• Interpretation of LVAD-related hemodynamics based
on noninvasive, invasive, and console data
• Supraventricular and ventricular arrhythmias pertinent
to the device, such as suction events with axial flow
devices (63)
• Hematological issues, including bleeding and throm-
bosis associated with antiplatelet and anticoagulant
therapy (64), and device-related hemolysis
• Infectious complications (65)
This HF specialist should also be knowledgeable in the
ollowing areas:
• Common symptoms and signs—dyspnea, fatigue, fe-
ver, anemia
• Device alarms
• Physiological and device-related factors affecting longevity
• Nutritional deficiency (66)
• Psychosocial status and quality of life (18)
• Right-heart catheterization data
• The role of exercise and rehabilitation therapy
. Additional Skills Required for Diagnosis
nd Treatment of Patients With Acute HF
.1. Initial Diagnosis and Management of Patients
ith Acute Decompensated HF
pisodes of acute decompensated heart failure (ADHF) are
he most common cause of hospitalization for patients with
dvanced chronic HF and, indeed, the most common reason
or hospitalization in all patients over age 65 years, resulting
n nearly 1 million hospitalizations annually in the United
tates (67). Approximately 80% of ADHF cases present to
he hospital emergency department (ED) (68), whereas the
emainder are identified during urgent visits to physicians’
ffices or clinics. Patients with ADHF often have chronic
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July 27, 2010:424–53 Competence for Heart Failure and TransplantationF, although as many as 30% of patients presenting with
DHF have no prior diagnosis of HF (68).
The HF specialist is experienced and knowledgeable
egarding ADHF, and knows that rather than a single
omogenous syndrome, ADHF encompasses multiple syn-
romes with varying presentations. These include sudden
flash” pulmonary edema or cardiogenic shock, or the more
nsidious exacerbation of HF resulting from myocardial
schemia or injury, chronic cardiomyopathy, hypertension,
olume overload, cardiac arrhythmias, and other scenarios
34,69–71). There may be a history of cardiac disease and
vidence of either systolic or diastolic ventricular dysfunc-
ion, cardiac rhythm abnormalities, or preload/afterload
ismatch (70,72,73). The HF specialist caring for patients
ith ADHF should have the cognitive skills to use the
linical history and findings on physical examination to
orm an accurate initial diagnostic assessment, supplement-
ng this with the results of laboratory studies (including
iomarkers), hemodynamic studies, and imaging.
Although ADHF is commonly the result of progressive
yocardial dysfunction, it is often precipitated by concom-
tant cardiac or systemic disease (Table 5). Among the most
requent are myocardial ischemia, arrhythmias (e.g., atrial
brillation), and uncontrolled hypertension. The latter is a
articular problem in patients of African-American ethnic-
ty (74). The HF specialist should demonstrate the cognitive
kills outlined in Table 5 so as to identify these and other
otential causes of decompensation and develop a plan to
odify these etiological factors through judicious therapeu-
ic intervention. The HF specialist should make use of
nowledge of the pertinent circulatory, respiratory, and
eurohumoral abnormalities to design an initial treatment
lan in the ED or urgent care setting. These abnormalities,
eviewed later, form the core competencies in this area.
The HF specialist knows that assessment of the hemo-
ynamic status of the patient with ADHF is essential to
eveloping the initial management plan. They know how to
ake decisions regarding the need for invasive versus
able 5. Precipitating Factors and Comorbidities Requiring Spe
cute Decompensated Heart Failure
Precipitant
yocardial ischemia/infarction
trial or ventricular arrhythmia
alvular disease (mitral regurgitation)
nfection, cardiac or systemic
ietary/pharmacological nonadherence
oncomitant administration of agents that cause sodium retention (e.g., nonste
anti-inflammatory agents) or nephrotoxicity (intravenous contrast dye)
nemia
ncontrolled hypertension
yperthyroidism
ypothyroidism
regnancyoninvasive assessments of hemodynamics. They should be sble to categorize the patient’s status according to a 2  2
rofile as either warm or cold (warm is equivalent to normal
erfusion and cold implies impaired systemic perfusion) or
s wet or dry (wet being elevated and dry being low-to-
ormal ventricular filling pressure) (75), as this rubric is
seful in formulating an initial approach to management.
he majority of patients with ADHF are either normoten-
ive or hypertensive (i.e., warm) (76). The HF specialist
ecognizes that the possible need for urgent pharmacological
r mechanical circulatory support must be considered for
he minority who has hypotension.
The HF specialist is aware that many patients with
DHF display impaired systemic perfusion due to de-
reased cardiac output, and in these cases, early initiation of
asodilator pharmacotherapy may be beneficial. A retro-
pective review of nearly 8,000 such cases in the Acute
ecompensated HF Registry (ADHERE) found that va-
odilator therapy started in the ED, rather than delayed
ntil the patient was admitted to a hospital ward, was
ssociated with an abbreviated hospital stay and lower
npatient mortality (77). The HF specialist should have a
orking knowledge of vasodilators such as nitroprusside,
itrates, hydralazine, and nesiritide, each of which has
nique pharmacological pathways (78). As many patients
ith ADHF have acute or chronic renal insufficiency,
nowledge of the effects of vasodilator agents on renal
erfusion and function is important to guide selection of the
ppropriate agent and dose. This allows for rapid deploy-
ent of these therapies leading to improved short and
ong-term outcomes. Furthermore, for those patients with
hronic HF, the specialist initiating treatment must con-
ider adjustment of chronic vasodilator therapies such as
ngiotensin-converting enzyme inhibitors, angiotensin-II
eceptor blockers, hydralazine, and organic nitrates.
The HF specialist should be competent to recognize
atients with diminished cardiac output who are unable to
olerate vasodilator therapy and who need agents that
ncrease myocardial contractility or mechanical circulatory
zed Cognitive Skills to Identify and Treat Patients With
Skill
Electrocardiography, acute coronary syndrome management
Electrocardiography, arrhythmia management
Cardiac auscultation, echocardiography
Cardiac auscultation, radiography interpretation, echocardiography
Knowledge of cardiovascular pharmacology
Knowledge of renal pharmacology
Intravenous vasodilator administrationciali
roidalupport. In ADHF, patients often present with life-
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Competence for Heart Failure and Transplantation July 27, 2010:424–53hreatening respiratory failure necessitating rapid treatment.
ssessment of the adequacy of ventilation and oxygenation
s an important aspect of the initial evaluation. Recent
dvances in noninvasive techniques, such as continuous
ositive airway pressure and bi-level positive pressure ven-
ilation, may reduce the need for endotracheal intubation
79,80). HF specialists caring for patients with ADHF
hould be familiar with the deployment of these therapies
nd/or anxiolytic and other adjunctive agents that may
mprove the patient’s ability to tolerate and benefit from
oninvasive ventilatory support. The specialist must also be
ble to identify situations in which noninvasive ventilation is
nappropriate or unsuccessful and mechanical ventilation is
ecessary.
Approximately 70% of patients with ADHF have signs
nd symptoms of elevated ventricular filling pressures such
s dyspnea, edema, or pulmonary congestion (81) resulting
ither from retention of sodium and water or central
edistribution of intravascular volume. Loop diuretics such
s furosemide, torsemide, and bumetanide are the mainstay
f treatment for volume overload, and knowledge of the
harmacology of each these agents enables the specialist to
elect the most appropriate agent, dose, and route of
dministration. The HF specialist should also recognize the
eleterious effects of excessive use of diuretics mediated by
eurohumoral activation (82), and select the lowest effective
ose. Conversely, resistance to diuretic therapy also occurs,
nd HF specialists must be able to reassess the initial
iuretic treatment plan, and adjust the dose of diuretic
edication, make use of synergistic diuretic agents, and
nitiate therapies that augment cardiac output and renal
lood flow as indicated on the basis of the patient’s response
nd changing status.
The HF specialist must assess how to balance the
atient’s chronic medical regimen, including neurohumoral
lockade, against the hemodynamic derangements arising
uring ADHF. The HF specialist knows that the initial
reatment of a patient with ADHF should be directed not
nly toward correction of symptoms and hemodynamic
bnormalities, but also at minimizing further myocardial
nd other end-organ injury.
Once the initial management plan is developed for the
atients with ADHF, the HF specialist must decide
hether hospitalization is necessary or the patient may be
afely released from the urgent care setting with close
utpatient follow-up. Indications for hospitalization of pa-
ients with ADHF are summarized in practice guidelines
ssued by the HFSA (83), outlined in Table 6. In addition,
atients with a new diagnosis of HF or other comorbidities
ot mentioned in the guidelines should be considered for
ospital admission. The HF specialist must be able to
dentify these characteristics and select an appropriate level
f inpatient monitoring and nursing care. The specialist
racticing in a facility without advanced invasive cardiac
onitoring or mechanical support capabilities should beble to identify patients likely to require these services and crrange the patient’s transfer to a fully equipped institution.
he HF specialist should have thorough knowledge of
hysiologic changes that occur in women who experience
outine pregnancy, who have HF, and who have undergone
eart transplantation and be thoroughly knowledgeable how
o manage these patients.
.2. Inpatient Management of Patients With ADHF
ollowing hospital admission, care of the patient with
DHF should adhere to principles addressed initially while
ssessing the effectiveness of therapy and modifying the
egimen as indicated. This may include titration of vasodi-
ator or inotropic therapy and invasive hemodynamic mon-
toring in those with uncertain hemodynamic status or
orsening symptoms and signs of HF. HF specialists must
hus be proficient at noninvasive assessment of volume and
erfusion status, and have access to personnel skilled in right
nd left heart catheterization. The specialist should be able
o interpret hemodynamic data obtained by invasive moni-
oring, and alter therapy in response to hemodynamic
ariation.
ADHF (Table 5) may develop in hospitalized patients as
result of myocardial ischemia, arrhythmia, infection, or
xposure to nephrotoxic agents, and the HF specialist must
e skilled in the identification of these etiologies as a
omponent of initial evaluation and treatment. HF special-
sts should also be able to recognize and manage common
ulmonary and renal comorbidities, particularly in patients
efractory to diuretic therapy or in those whose renal
unction deteriorates. Depending on the definition, the
ardiorenal syndrome develops in 25% to 45% of patients
ith ADHF (84), and increases mortality (85). The HF
pecialist should have experience managing patients with
ultisystem organ failure in collaboration with consultants
n other subspecialties.
As symptoms of ADHF improve and volume status is
able 6. Characteristics of Patients With Acute
ecompensated Heart Failure Indicative of the Need
or Hospitalization
espiratory distress (respiratory rate 40 breaths per min) or hypoxia
(oxygen saturation 90%)
ulmonary edema (determined by radiograph)
nasarca or significant edema (2) or a weight gain of 5 kg over
optimum weight
yncope or hypotension (systolic blood pressure 80 mm Hg)
iminished end-organ perfusion, as may be evidenced by worsening
renal function or altered mental status
emodynamically significant atrial or ventricular arrhythmia
ajor metabolic or electrolyte disturbance
ongestive heart failure of recent onset (no past history)
vidence of myocardial ischemia or infarction (chest pain symptoms)
nadequate social support for outpatient management
ailure of outpatient management
oncomitant acute medical illnessorrected, the HF specialist should be competent to develop a
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July 27, 2010:424–53 Competence for Heart Failure and Transplantationransitional treatment plan to address appropriate criteria for
ospital discharge (Table 7). At this point, the HF specialist
nderstands how to assess the patient’s long-term treatment
rogram, including consideration of such advanced therapies as
lectrical resynchronization, transplantation, or mechanical
irculatory support, based upon a fund of knowledge that
ncludes current practice guidelines and appropriate use crite-
ia. Perhaps most important, the ADHF hospitalization rep-
esents a valuable opportunity for the HF specialist to review
voidable events that may have provoked decompensation. In
any centers, the team approach is used to care for patients
ith Stage D HF, including pretransplant and posttransplant
eeds. The HF specialist should be skilled in team manage-
ent. These teams usually include advanced nurses, fellows,
echnicians, and others.
The HF specialist is competent to organize and supervise
HF disease management program, and should be familiar
ith the multidisciplinary disease management approach.
hough systems of care vary, most focus on patient educa-
ion and self-monitoring, identification of comorbidity and
pplication of evidence-based therapy. Many include home
isits and/or telephonic or video monitoring, some of which
educe hospital readmission, cost, and to a lesser extent,
ortality (86–91). Awareness of the availability of such
rograms in the specialist’s practice region becomes espe-
ially important at the time of hospital discharge.
.3. Avoiding Repeated Hospital Admissions
ospital readmissions for HF are common and consume a
arge parcel of healthcare dollars. The major causes of
eadmission include dietary indiscretion, medication non-
ompliance, and intercurrent illness such as a respiratory
ract infection. Prevention of readmission is an important
spect of the management of HF patients, and the HF
pecialists caring for patients who have been repeatedly
ospitalized must be able to identify and ameliorate the
actors contributing to readmission.
The HF specialist should be thoroughly familiar with the
able 7. Discharge Criteria for Patients With Heart Failure
ecommended for all HF patients ● Exacerbating
● Near optimal
● Transition from
● Patient and fa
● LVEF docume
● Smoking cess
● Near optimal
(for patients w
● Follow-up clin
hould be considered for patients with advanced HF or
recurrent admissions for HF
● Oral medicatio
● No intravenou
● Ambulation be
● Plans for post
generally no lo
● Referral for di
CE indicates angiotensin-converting enzyme; HF, heart failure; and LVEF, left ventricular ejectioransition of care at the time of hospital discharge and identify Aatients likely to decompensate and require readmission. This
kill set allows the specialist to manage frequent follow-up
isits, carefully adjust medications, and develop a strategy for
urveillance of electrolytes and renal function.
The HF specialist should provide comprehensive educa-
ion to both patient and family about the disease process,
onpharmacological therapy and elements of self-manage-
ent, including but not limited to dietary sodium restric-
ion, and adherence to the medication regimen and follow-up
ppointments (92) (Table 8). The HF specialist must
ecognize that patients who are repeatedly hospitalized with
ecompensation may benefit from comprehensive HF man-
gement. Both the ACCF/AHA guidelines for the diagno-
is and management of chronic HF in the adult (28) and the
FSA Comprehensive Heart Failure Guideline (34) rec-
mmend multidisciplinary disease management programs
or patients at risk of clinical deterioration or readmission to
ddress barriers to adherence and reduce hospitalization. If
program is not available at the clinician’s institution, the
F specialist should be familiar with and establish a referral
elationship with a disease management program elsewhere.
he HF specialist should facilitate integration and coordi-
ation of care with primary care physicians, internists, and
ther groups, including cardiac rehabilitation and home
ursing services. They should be familiar with the variable
oles of the advanced practice nurse and the registered nurse
n the disease management clinic to maintain compliance
ith the board of nursing.
addressed
e status achieved
venous to oral diuretic successfully completed
ducation completed, including clear discharge instruction
counseling initiated
acologic therapy achieved, including ACE inhibitor and beta-blocker
duced LVEF), or intolerance documented
scheduled, usually for 7 to 10 d
imen stable for 24 h
dilator or inotropic agent for 24 h
ischarge to assess functional capacity after therapy
rge management (scale present in home, visiting nurse or telephone follow up
than 3 d after discharge)
management, if available
ion. Reproduced with permission from the Heart Failure Society of America (34).
able 8. Patient Self-Care Practices After Hospital Discharge
nowledge of clinical follow-up visit
erforming daily weigh-in
ollowing specific sodium restriction
ollowing specific fluid restriction
ot smoking
lan for reporting worsened symptoms
erforming physical activity 3 times/wk
lexible diuretic regimen for weight gainfactors
volum
intra
mily e
nted
ation
pharm
ith re
ic visit
n reg
s vaso
fore d
discha
nger
seasedapted with permission from Koelling et al. (92).
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equired for Referring and Monitoring of
atients With Electrophysiologic and
emodynamic Devices
.1. Referral of Patients for
lectrophysiologic Devices: ICDs
considerable body of evidence, including definitive ran-
omized trials, indicates that ICDs prolong life by prevent-
ng sudden cardiac death both in primary and secondary
revention settings (93–102). The HF specialist should be
ully familiar with guidelines for selection of appropriate
atients for device implantation (103). An ICD should be
onsidered in a variety of clinical scenarios, and the ad-
anced HF specialist must develop a consistent approach to
valuation of patient candidacy. The HF specialist should
ave a coordinated plan of collaboration with the ICD
mplanting and monitoring physicians with common under-
tandings of appropriate indications. The HF specialist
hould be competent to manage the following scenarios:
Scenario 1: A patient with newly discovered HF is
admitted emergently to hospital for initial evaluation.
The etiology of HF is determined, and appropriate,
evidence-based therapy is initiated. Depending on the
etiology, comorbid conditions, response to therapy,
and long-term treatment plan, there is ambiguity
about the optimum timing of ICD implantation after
the onset of HF (104,105). The HF specialist should
weigh the evidence supporting early implantation
(within 3 months after onset of symptoms), and
develop a strategy for the use of ICD technology in
the individual patient on the basis of the likelihood of
improvement in cardiac function and other factors.
More important, follow-up must be arranged so that
the need for implantation can be re-evaluated over
time on the basis of changes in the patient’s clinical
condition.
Scenario 2: A patient with chronic Stage C HF and left
ventricular ejection fraction above 35% followed as an
outpatient has not been a candidate for ICD implan-
tation in the absence of pertinent symptoms. The HF
specialist must be competent to reevaluate symptoms
and cardiac function (left ventricular ejection frac-
tion), as eligibility for an ICD may change over time.
The HF specialist must have the necessary skills to
explain to the patient how the treatment regimen may
change to incorporate such a device.
Scenario 3: A patient with long-standing, advanced HF
and low left ventricular ejection fraction is hospital-
ized repeatedly. In view of its questionable ability to
prolong life because of the patient’s advanced age or
comorbidities, an ICD may not be recommended in
this case. Alternatively, this or other HF therapy,
pacemaker or cardiac resynchronization devices, or cinvestigational approaches such as a permanent me-
chanical circulatory assist device (i.e., destination
VAD) therapy may be appropriate. The HF specialist
must weigh the potential benefits of ICD implanta-
tion and other advanced interventions in complex
clinical situations.
These clinical scenarios, and others too numerous to
atalogue, indicate the need for integrated knowledge de-
ived from randomized trials, clinical practice guidelines,
xperience with HF patients with ICD devices, and sea-
oned clinical judgment. The HF specialist must be pre-
ared to serve as a clinical resource in reaching decisions
bout these vital issues in the care of individual patients.
.1.1. Monitoring Patients With Electrophysiologic
evices: ICDs
he optimal management of a patient with HF and an ICD
egins with identification of the responsible clinicians in-
olved in the patient’s care to facilitate communication and
ocumentation. Fragmentation of care between primary
are clinicians, electrophysiologists, cardiologists, and HF
pecialists is detrimental. With respect to the HF patient
ith an ICD, the HF specialist has 3 general areas of
esponsibility, delineated as follows (106–113).
.1.1.1. COORDINATION OF CARE
t is a reasonable expectation that in some settings, the HF
pecialist will manage HF therapy and monitor implantable
evices in patients with complex HF. This reflects the
pecialized skills and required competence of secondary
ubspecialties that have developed in cardiac electrophysi-
logy and advanced HF cardiology. The equipment neces-
ary to interrogate ICDs and other cardiac arrhythmia
evices may not be readily available in the office of the HF
linician, though in the future, this barrier may be overcome
y the availability of downloaded device information on a
ecure Web site, making it accessible to all of the patient’s
roviders. Nevertheless, the HF specialist must integrate
nformation derived from ICD interrogation with other
lements of the evaluation and management of the patient
ith HF. If device interrogation detects episodes of atrial
igh-rate activity suggestive of paroxysmal atrial fibrillation
e.g., mode switches), or a decrease in maximum heart rate
uggestive of reduced physical activity, it may be appropriate
o modify other aspects of the HF treatment regimen
ccordingly. Training requirements for certification in ad-
anced HF and transplant will eventually include compe-
ence in ICD and CRT interrogation, but this is not a
equirement for competence at present. Nevertheless, it is a
seful skill set.
A number of device features, including estimation of
olume status, are emerging that may facilitate earlier
rediction of HF decompensation. The additional data
erived from these ICD features will provide the HF
pecialist additional information, and the HF specialist may
onsider development of a method for information manage-
m
r
t
t
6
C
A
t
s
I
s
r
b
m
o
f
s
m
t
c
m
u
6
W
T
t
v
1
p
s
a
a
r
m
p
t
a
a
m
V
6
P
I
t
a
w
p
T
t
i
i
m
a
t
c
A
n
c
s
i
i
s
a
t
d
t
6
T
C
s
b
m
w
v
s
d
s
s
a
7
T
C
V
c
c
(
p
d
t
*
443JACC Vol. 56, No. 5, 2010 Francis et al.
July 27, 2010:424–53 Competence for Heart Failure and Transplantationent that includes timely data acquisition, storage and
etrieval, linkages to treatment protocols, and communica-
ion among members of a well-organized team of clinicians
o assure optimal patient care (114–116).
.1.1.2. RESPOND TO CHANGES IN THE CLINICAL STATUS OF THE PATIENT, AND
ONSIDER THE IMPACT ON APPROPRIATE ICD MANAGEMENT
dvanced HF often necessitates adjustment of ICD set-
ings, and the HF specialist or a member of the HF team
hould be prepared to adjust (or recommend adjustment of)
CD settings in response to changes in the patient’s HF
tatus. Examples include the onset of atrial fibrillation with
apid ventricular response, development of symptomatic
radycardia, development of a need for CRT, the develop-
ent of increasing frequency of ventricular tachycardia and
ther arrhythmias leading to ICD discharges as a risk factor
or clinical deterioration, or irreversible deterioration in HF
ymptoms warranting hospice care. These and other com-
on clinical developments mandate not only a change in
he course of HF therapy, but also discussion with the
linician managing the ICD to ensure appropriate imple-
entation and adjustment of detection algorithms, and
pgrading or inactivation of the device.
.1.1.3. PARTICIPATE IN MANAGEMENT OF ARRHYTHMIAS IN THE PATIENT
ITH AN ICD
he HF specialist must understand the risks and benefits of
he various options available for management of atrial and
entricular arrhythmias in the patient with HF (109,111,
13). Cardiac electrophysiologists involved in the care of
atients with HF sometimes seek input from the HF
pecialist to select the appropriate treatment. Ongoing
rrhythmias may prompt additional diagnostic testing, such
s coronary imaging or myocardial biopsy. Likewise, ar-
hythmias such as atrial flutter, atrial fibrillation, recurrent
onomorphic ventricular tachycardia requiring ICD appro-
riate or inappropriate therapies; or arrhythmias that reduce
he hemodynamic impact of CRT may require consider-
tion of catheter or surgical ablative procedures. Finally,
cceleration of arrhythmias coincident with advanced HF
ay prompt a decision about cardiac transplantation or
AD therapy.
.2. Cardiac Resynchronization Therapy
atients with New York Heart Association functional class
II or ambulatory class IV HF on appropriate medical
herapy who have QRS durations greater than 120 ms have
class I indication for CRT. This type of device, with or
ithout ICD capabilities, has been demonstrated to im-
rove symptoms and reduce mortality in patients with HF.
he HF specialist should understand the clinical utility of
his technology, support its use when appropriate, and assist
n the longitudinal care of patients with this type of
mplanted device.
Successful CRT use requires that the HF specialist or a
ember of the HF team understand the indications, short-nd long-term complications, methods of device optimiza-
C
wion, and elements of long-term follow-up. This is a
hallenging task and is best embraced with a team approach.
n emerging model is the CRT/HF clinic, where the
ecessary component resources (including a HF specialist,
ardiac electrophysiologist, and echocardiographer), are as-
embled to provide a rarefied level of care that facilitates
dentification of appropriate candidates, longitudinal mon-
toring, and device troubleshooting. Likewise, the HF
pecialist should understand the importance of and encour-
ge direct lines of communication between dedicated elec-
rical device nurse specialists and HF advanced practice and
isease management nurses, with oversight and input from
he HF specialist and electrophysiologist.
The cognitive competencies required include:
• Skill in optimizing evidence-based medical therapy for
HF.
• Familiarity with the guidelines regarding indications
for CRT versus combined CRT with ICD.
• Awareness of the acute complications associated with
CRT, including the identification of lead placement
errors, especially lead migration.
• Familiarity with the uses and limitations of echocar-
diographic measures of mechanical dyssynchrony.*
• Understanding the use of echocardiography to opti-
mize biventricular pacing, including interventricular
and atrioventricular synchrony.*
.3. Interpreting Data From Implantable Devices
hat Monitor Volume Status
ertain implantable devices provide adjunctive clinical as-
essments beyond arrhythmia surveillance, pacing, or defi-
rillation and have the potential to augment clinical decision
aking. Impedance monitoring is presently available,
hereas implantable hemodynamic monitoring remains in-
estigational. The HF specialist should be aware of various
trategies that may be used to monitor volume and hemo-
ynamic status in ambulatory patients with HF. The HF
pecialist should be prepared to access, interpret, and apply
uch data in clinical practice as these new devices emerge
nd are approved.
. Management of Advanced HF and
ransplantation in Patients With
ongenital Heart Disease
ast improvement in the outcomes of surgery to repair
omplex congenital heart disease over the past 25 years has
reated a growing population of survivors who develop HF
10,117–120). The most common etiologies of HF in this
opulation are systemic ventricular dysfunction, right heart
ysfunction, and low cardiac output due to poor flow
hrough a palliated Fontan circuit. In addition, hypoxemia
It is assumed that the physician interpreting echocardiograms for the purposes of
RT implantation and management will have at least Level 2 training (consistent
ith that of a cardiology fellow).
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Competence for Heart Failure and Transplantation July 27, 2010:424–53elated to cyanosis can worsen ventricular function and
xacerbate HF. Advanced HF is found in all age ranges of
atients with congenital heart disease, but occurs more
ommonly in the adolescent and young adult. The HF
pecialist caring for the congenital heart disease patient with
dvanced HF should be able to identify the need for the
ervices of an adult or pediatric cardiologist and surgeon
ith expertise in congenital heart disease and be able to
oordinate the care of these patients across the multiple
isciplines. It is not expected that the nuances in the care of
atients with congenital heart disease in need of heart
ransplantation or MCADs is a core competence of the HF
pecialist. However, the HF specialist should be familiar
ith such patients and the need for ancillary services of
ther experts in this field.
.1. HF Management
he common congenital heart defects that result in chronic
F are obstructive lesions of the left ventricular outflow
ract, systemic right ventricular anatomy—such as corrected
-transposition or d-transposition following an atrial-switch
rocedure and single ventricular anatomy. The HF special-
st† should be able to recognize the manifestations of systolic
nd diastolic dysfunction associated with these lesions. In
ddition, the HF specialist should be able to recognize
rimary right ventricular dysfunction and right HF follow-
ng repair of the tetralogy of Fallot or resulting from
ulmonary vascular disease. The HF specialist† must also be
ble to evaluate the causes of low cardiac output in patients
ith a Fontan circuit and normal ventricular function.
eurohumoral activation in patients with HF due to con-
enital heart disease is different from that in patients with
V dysfunction, particularly when the systemic ventricle is
ot a morphological left ventricle (121). As a result, HF
atients with congenital heart disease have variable re-
ponses to angiotensin-converting enzyme inhibition and
eta-adrenergic blockade, and the HF specialist¡ must be
ble to tailor medical therapy to the specific congenital
efect (122). The HF specialist† should be able to recognize
achyarrhythmias and bradyarrhythmias in patients with
ongenital heart disease and possess the cognitive skills to
etermine the benefit of different pacing modalities to
nhance cardiac output and lessen the risk of sudden death.
lthough retrospective studies have suggested clinical and
chocardiographic improvement with the use of CRT in
atients with congenital heart disease, prospective studies of
fficacy have not been performed (123). The HF specialist†
hould be able to assess the potential benefit of CRT
herapy in selected patients with congenital heart disease.
.2. Transplantation Evaluation
he HF specialist† should also be able to interpret addi-
ional studies, such as lung ventilation and perfusion scans,
ardiovascular magnetic resonance or computed tomogra-s
This mention of HF specialist refers to adult, pediatric, or surgical colleagues with
pecial expertise in the care of adolescents and adults with congenital heart disease.hy imaging, and pulmonary and liver function testing that
re often necessary to evaluate the transplant candidacy of
atients with congenital heart disease. The HF specialist†
hould have expertise in the use of pulmonary vasodilators
or evaluation and therapy in congenital heart disease
atients with elevated pulmonary vascular resistance. He or
he should be able to identify anatomic and surgical factors
ssociated with the underlying congenital defect that would
equire surgical intervention at the time of transplantation.
uman leukocyte antigen sensitization is common in pa-
ients following congenital heart disease surgery, and the
F specialist† should be familiar with the evaluation and
reatment of human leukocyte antigen sensitization pre- and
osttransplantation. The HF specialist should have the skill
o evaluate functional capacity in a patient with congenital
eart disease in the context of lower than normal expected
alues (124–126).
An increasing number of patients with single ventricle
hysiology palliated with the Fontan procedure are being
eferred for transplantation due to ventricular failure or
omplications from high venous pressures in the Fontan
ircuit. These complications include intractable atrial ar-
hythmias, protein-losing enteropathy, cachexia, ascites, and
hronic pleural or pericardial effusions. The need for exten-
ive reconstructive surgery and the debilitated pretransplant
tate of these patients has resulted in a higher mortality
ollowing transplantation compared to patients with cardio-
yopathy (127). The HF specialist† must have the cognitive
bilities to assess the suitability of transplantation in the
ontan patient and be able to counsel the patient and the
amily regarding the potential risks and benefits.
The patient with congenital heart disease often has a
trong family support system, and the HF specialist† should
e able to provide family-centered care, particularly in the
etting of palliative or end-of-life care. The HF specialist†
hould be able to coordinate services such as social work,
sychiatry, and hospice to support not only the patient, but
he family as well.
.3. Mechanical Device Support
n a large multicenter series of pediatric patients, 22% of
hose receiving device support (other than an extracorporeal
embrane oxygenator, or ECMO) had a diagnosis of
ongenital heart disease, which was an independent risk
actor for adverse outcome (11). The use of mechanical
evice support in the congenital heart disease patient
equires knowledge of the anatomic and physiologic factors
uch as body size, residual intracardiac shunts, the presence
f a single ventricle, or venous anomalies and/or arterial
nomalies that may impact the success of device implanta-
ion, and the effectiveness of the VAD support. The HF
pecialist† should have the cognitive skills to evaluate the
ndications for VAD use in patients with congenital heart
isease and be able to compare the relative risks of VAD
upport with medical therapy or palliative care.
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revious congenital heart disease has important implications
or posttransplantation management. The heart transplan-
ation specialist should be aware of the potential for residual
natomical defects, such as pulmonary artery or aortic arch
tenosis, venous anomalies, aortopulmonary collaterals, or
rteriovenous malformations. These can lead to low cardiac
utput following transplantation. The HF specialist† should
e able to assess the indications and contraindications of the
atheter- or surgical-based interventions available to treat
hese residual defects. Bacterial and viral infectious compli-
ations are common following transplantation in patients
ith congenital heart disease, and the specialist should be
ware of the need for increased surveillance.
.5. Summary
he HF specialist is not expected to be as well-versed in the
uances of congenital heart disease as pediatric congenital
eart disease subspecialists; conversely, congenital heart
isease subspecialists may not be able to fully assess the
mpact of advanced HF management and transplantation in
his population. Collaboration between physicians with
xpertise in these areas is necessary to provide optimal
atient care. Thus, the HF specialist who undertakes the
are of a patient with congenital heart disease and advanced
F must practice in an environment with the expertise in
he medical, surgical, and allied health care of the patient
ith complex congenital heart disease. In general, this
ould be a center with an active pediatric and adult
ongenital heart disease program.
. End-of-Life Issues
.1. Referring Patients With Advanced HF for
alliative Care
espite advances in pharmacology and devices, advanced
F remains a disorder with substantial morbidity and
ortality. At the end stage of HF, therapies such as CRT,
CD, LVAD, and cardiac transplantation may not be
ppropriate or desired because of disability, comorbidity, or
he patient’s preferences. Providers specializing in the care
f patients with advanced HF should be able to recognize
nd-stage disease. HF can be associated with episodes of
cute decompensation with subsequent improvement, or the
ourse may be interrupted by sudden death unheralded by
orsening HF symptoms. Palliative care decisions require
xpertise in diagnosis and treatment of HF and its comor-
idities, and judgment about prognosis in the face of
ncertainty. HF care across the disease continuum should
ransition gradually from aggressive intervention to pallia-
ion, comfort, and ultimately bereavement care (128).
The HF specialist should be knowledgeable regarding
alliative care. The goal of palliative care is to prevent and
elieve suffering and support the best possible quality of life sor patients and their families, regardless of the stage of
isease or the need for concomitant therapy. Palliative care
xpands traditional disease-model medical treatment to
nclude the goals of enhancing quality of life for patients and
amily members, helping with decision-making, and pro-
iding opportunities for personal growth. Palliative care may
e rendered concurrently with life-prolonging treatment or
s the main focus of care (129). Class I recommendations
or palliative care for patients with advanced (Stage D) HF
re outlined in the ACCF/AHA Guidelines for the Diag-
osis and Management of Chronic HF in the Adult (28).
HF specialists should be equipped to screen for social,
nvironmental, and spiritual concerns that arise with debil-
tating illness. The HF specialist must have communication
kills to discuss the patient’s wishes and offer palliative care
ptions when appropriate, and should be acquainted with
he means available to manage symptoms such as pain,
yspnea, low mood, and anxiety (130,131). These include
harmacological and nonpharmacological modalities, pa-
ient and family education, and psychosocial and spiritual
upport. HF specialists should be comfortable discussing the
piritual, social, and emotional aspects of debilitating ill-
esses, including those specific to the patient’s cultural
ackground. The HF specialist should understand the
anagement of terminal symptoms and the natural history
nd management of grief and bereavement (132,133). Spe-
ifically, the HF specialist should master the skills enumer-
ted in the Institute of Medicine’s report on end-of-life
ssues, as appropriate for patients with advanced HF (Table 9)
134). The HF specialist or a member of the management
eam should be aware of and familiar with complex social,
nancial, or legal issues that may occur in patients with
dvanced HF (Table 10).
.2. Withdrawal of Life-Support Measures
t the end stage of HF, patients and/or their surrogates may
sk the specialist to withhold or withdraw life-prolonging
herapy and provide supportive or comfort-oriented care.
he decision to do so represents a specialized form of
alliative care, and assumes that the HF specialist has
cquired the cognitive and technical skills to provide pallia-
ive care.
HF specialists engaging in decisions about withdrawal of
ife support should possess the skills needed to meet the
oals of care enumerated in the Liverpool care pathway for
he dying patient, as appropriate for the patient with
nd-stage heart disease (Table 11) (136). A detailed de-
cription of the technical skills needed to withdraw mechan-
cal ventilation is beyond the scope of this guideline and
iscussed elsewhere (137). Considerations specific to the
F specialist include weaning inotropic support, intra-
ortic balloon pump support, and LVADs, and deactivation
f defibrillators when the decision is made to withdraw
upport.
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.1. Maintenance of Competence—
linical Experience
aintaining Level 3 competence in advanced HF requires
ngoing experience evaluating and managing complex HF
atients in the face of an ever-increasing number of available
reatments. The literature does not support specific volume
argets to maintain competence in nonprocedural aspects of
atient care. Competence can be maintained through fre-
uent opportunities to care for expanded HF populations,
ncluding those requiring end-of-life hospice care, chronic
notropic drug infusion support, and individuals with HF
nd noncardiac organ transplantation. The more challeng-
ng cohorts of HF patients in the purview of the HF
pecialist are described in the ACCF 2008 COCATS 3
able 9. Professional Preparation for End-of-Life Patient Care
cientific and clinical knowledge and skills, including:
Learning the biological mechanisms of dying from major illnesses
and injuries
Understanding the pathophysiology of pain and other physical and
emotional symptoms
Developing appropriate expertise and skill in the pharmacology of
symptom management
Acquiring appropriate knowledge and skill in nonpharmacological
symptom management
Learning the proper application and limits of life-prolonging interventions
Understanding tools for assessing patient symptoms, status, quality of life,
and prognosis
nterpersonal skills and attitudes, including:
Listening to patients, families, and other members of the healthcare team
Conveying difficult news
Understanding and managing patient and family responses to illness
Providing information and guidance on prognosis and options
Sharing decision making and resolving conflicts
Recognizing and understanding one’s own feelings and anxieties about
dying and death
Cultivating empathy
Developing sensitivity to religious, ethnic, and other differences
thical and professional principles, including:
Doing good and avoiding harm
Determining and respecting patient and family preferences
Being alert to personal and organizational conflicts of interests
Understanding societal/population interests and resources
Weighing competing objectives or principles
Acting as a role model of clinical proficiency, integrity, and compassion
rganizational skills, including:
Developing and sustaining effective professional teamwork
Understanding relevant rules and procedures set by health plans, hospitals,
and others
Learning how to protect patients from harmful rules and procedures
Assessing and managing care options, settings, and transitions
Mobilizing supportive resources (e.g., palliative care consultants,
community-based assistance)
Making effective use of existing financial resources and cultivating
new funding sources
eprinted with permission from the National Academies Press, Copyright 1997, National
cademy of Sciences (134).raining statement (8) as follows:. Patients evaluated for cardiac transplantation or mechan-
ical assist devices
. Patients who have undergone cardiac transplantation
. Patients with HF and mechanical circulatory assist devices
. Patients with HF evaluated for ICD and CRT devices
. Device interrogation and interpretation in patients with
implanted ICD or ICD-CRT devices
Establishing clinical requirements for physicians who care
or patients undergoing heart transplantation is equally
ifficult, due in part to the relatively small number of heart
ransplants performed each year in the United States (2,192
n 2006) (138). To maintain competence in heart transplan-
ation, the committee recommends participation as a mem-
er of a team in an institution with a robust transplant
rogram, one that cares for patients during all phases of the
ransplant process—pretransplant, perioperatively, and
osttransplant.
.2. Continuing Medical Education
ontinuing medical education (CME) is an important
athway to sustained competence in a field as broad as HF
anagement. Remaining current with research and guide-
ines presents a particular challenge to the HF specialist
ecause of the rapidly changing nature of the field. All states
equire CME as a condition of licensure. It is not the intent
f this document to stipulate the number of credits required,
r to specify in which of the many currently available forums
hese credits should be obtained. HF specialists should
oncentrate a considerable proportion of their CME time in
F; related areas in cardiology; and other related disci-
lines, as delineated in Section 3 of this document (Com-
onents of Competence Required for the Management of
atients With Heart Failure). Category 1 CME credits
hould be obtained from organizations certified by the
ccreditation Council for Continuing Medical Education
ACCME).
0. Institutional Competence
t is not the purpose of this committee to pass judgment on
he competence of an individual’s institution. However, the
able 10. Social Issues Regarding Heart Transplantation and
entricular Assist Device Replacement
he advanced heart failure specialist should:
Have a close working relationship with the institution’s social worker and
region’s social service agencies
Have familiarity with the state’s laws with respect to the care of the indigent
and under- or uninsured
Be aware of programs maintained by county and state agencies and
pharmaceutical firms, device manufacturers, and home care agencies to
provide aid to those incapable of paying for their medication
Be thoroughly familiar with the rights patients have under the Americans
With Disabilities Act (135) and should be comfortable assessing patients’
claims for disability
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July 27, 2010:424–53 Competence for Heart Failure and Transplantationommittee recognizes that the advanced HF and transplan-
ation specialist should practice in association with an
nstitution that provides the personnel and infrastructure
ecessary to deliver comprehensive, integrated care. The
dvanced HF and transplantation specialist should be part
f a multidisciplinary team composed of specialists with
ompetence in the management of HF, transplantation, and
heir associated comorbidities. The availability of cardiotho-
acic surgeons with expertise in management of high-risk
atients with ischemic or valvular heart disease, VADs, and
ransplantation is essential. In centers where transplantation
s performed in patients with congenital heart disease,
xpertise in complex congenital heart disease surgery should
e available. Subspecialists in nephrology, neurology, anes-
hesiology, critical care, infectious diseases, immunology,
nd oncology who have competence in the management of
omorbidities associated with HF and transplantation
hould be available.
The benefits of a comprehensive disease management
pproach to patients with HF has been well documented in
erms of morbidity and long-term survival (139,140). The
nstitutional competencies that contribute to successful HF
are delivery include the ability to develop and disseminate
ducational and counseling materials, the inclusion of spe-
ialized nurses and/or nurse practitioners, the availability of
ocial service and financial counseling, and the implemen-
ation of clinical information systems that facilitate transfer
f information among providers (141). Dietary counseling
nd cardiac rehabilitation have also been identified as
aking important contributions to a comprehensive HF
anagement program. The above competencies apply as
ell to institutions providing care to patients requiring
ADs or transplantation, despite the diverse clinical situa-
able 11. Goals of Care for Dying Patients
omfort measures
Goal 1—Current medication assessed and nonessentials discontinued
Goal 2—As required, subcutaneous drugs written up according to protocol (pa
Goal 3—Discontinue inappropriate interventions (blood tests, antibiotics, intra
document not for cardiopulmonary resuscitation
sychological and insight issues
Goal 4—Ability to communicate in English assessed as adequate (translator n
Goal 5—Insight into condition assessed
eligious and spiritual support
Goal 6—Religious and spiritual needs assessed with patient and family
ommunication with family or others
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uality transplantation services in a Medicare-participating
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ule: Medicare Program; Hospital Conditions of Partici-
ation: Requirements for Approval and Re-Approval of
ransplant Centers to Perform Organ Transplants (142).
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nd operated in accordance with 372 of the Public Health
ervice Act (42 USC section 274).
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